None
EN
FDA clears IND for Brightpath’s BP-2202 for multiple myeloma
[]
BioWorld
Immuno-oncologyBrightpath Biotherapeutics Co. Ltd. has gained IND clearance from the FDA for BP-2202, enabling initiation of a first-in-human phase I trial in patients with relapsed or refractory multiple myeloma.
Dosing will begin later this year.